SG&A Efficiency Analysis: Comparing CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd.

Comparing SG&A strategies of CymaBay and Taro Pharmaceuticals.

__timestampCymaBay Therapeutics, Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014818500091733000
Thursday, January 1, 2015887100087644000
Friday, January 1, 2016964500092365000
Sunday, January 1, 20171238700085656000
Monday, January 1, 20181438100088196000
Tuesday, January 1, 20191923800089971000
Wednesday, January 1, 20201742500093413000
Friday, January 1, 20212304000091355000
Saturday, January 1, 202225116000113676000
Sunday, January 1, 202351953000198366000
Monday, January 1, 2024218935000
Loading chart...

In pursuit of knowledge

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding operational efficiency is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, CymaBay's SG&A expenses surged by over 500%, peaking in 2023. In contrast, Taro's expenses grew more modestly, increasing by approximately 116% during the same period. This stark difference highlights CymaBay's aggressive expansion strategy, while Taro maintains a more conservative approach. Notably, in 2023, Taro's SG&A expenses were nearly four times higher than CymaBay's, reflecting its larger scale of operations. However, the absence of data for CymaBay in 2024 leaves room for speculation on its future trajectory. This comparative analysis underscores the diverse strategies within the pharmaceutical sector, offering insights into how companies allocate resources to drive growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025